Does Medi-Cal Cover Spravato? Eligibility, Plans, and Costs

Yes, Medi-Cal does cover Spravato (esketamine) for adults with treatment-resistant depression or major depressive disorder with acute suicidal ideation, but coverage runs through Medi-Cal Rx with prior authorization, step-therapy documentation, and administration at a REMS-certified clinic. The drug itself is authorized by Medi-Cal Rx, while the in-clinic administration and two-hour monitoring are billed to the patient’s managed care plan.¹

Who Qualifies Under Medi-Cal’s Criteria

Spravato is FDA-approved for adults with treatment-resistant depression, meaning major depressive disorder that has not responded to at least two oral antidepressants, and separately for adults with depressive symptoms accompanied by acute suicidal ideation or behavior.² Medi-Cal coverage tracks those indications, but individual managed care plans layer on their own clinical documentation requirements.

Blue Shield of California’s Medi-Cal policy requires a baseline depression score using a validated tool such as the PHQ-9 or MADRS, documented inadequate response to two medications from different antidepressant classes (or documented intolerance to all classes), and a prescriber who is a psychiatrist or has consulted with one. Initial authorization runs two months, with reauthorization up to six months if the patient improves clinically.³

Molina Healthcare wants documented failure of two formulary antidepressant classes with at least six weeks of consistent therapy on each, a baseline depression score, psychiatrist or behavioral health specialist involvement, and attestation of pre- and post-dose monitoring. Molina’s initial approval for treatment-resistant depression is four weeks, with continuation for six months.⁴

Some Centene-affiliated plans go further. They require a PHQ-9 baseline of at least 15 and add a third step on top of the two failed antidepressants: documented failure of an augmentation therapy such as lithium, a second-generation antipsychotic, thyroid hormone, or buspirone for at least four weeks.⁵ Which plan a patient belongs to changes how much prior treatment history the file needs to show.

How the Request Gets Submitted

California’s Medi-Cal pharmacy benefit is carved out to Medi-Cal Rx, a fee-for-service program administered by Magellan Medicaid Administration for the Department of Health Care Services. The provider submits a Treatment Authorization Request for the drug directly to Medi-Cal Rx using the DHCS 6560 form, filed electronically through CoverMyMeds, by fax, or by mail.⁶ The final coverage decision on the drug itself sits with Medi-Cal Rx, not the managed care plan.¹

Under California law, Medi-Cal Rx must respond to a prior authorization request within 24 hours of receiving it. If clinical documentation is missing, the request is deferred and the provider has 30 calendar days to supply it; if nothing arrives in that window, the request is denied.⁷ The administration and observation portions of each session are billed separately to the managed care plan using standard evaluation-and-management and procedure codes, and those services typically do not need additional plan authorization.¹

Why Coverage Can Look Different Depending on Your Plan

Medi-Cal is administered through more than 25 managed care plans across the state, and each one writes its own clinical criteria for the medical-benefit side of Spravato. A 2025 cross-sectional analysis of 165 Medicaid policy-making entities nationwide found that 96% of those covering esketamine require prior authorization, and because managed care organizations control most Medicaid decision points, “intrastate inconsistencies are common.”⁸ Two Medi-Cal patients with identical treatment histories can face different documentation requirements and different approval timelines based on which plan they are enrolled in.

The Monotherapy Gap After the 2025 Label Change

In January 2025, the FDA expanded Spravato’s label to allow it as a standalone treatment for treatment-resistant depression, removing the earlier requirement that patients also take an oral antidepressant.⁹ Payer coverage criteria have not automatically caught up. Many Medicaid plans still require concurrent oral antidepressant use as a condition of coverage.⁸ Whether Medi-Cal Rx and its California managed care plans have updated their criteria to match the new label is not confirmed in available documentation. If your prescriber wants to use Spravato without a companion antidepressant, expect the possibility of a denial rooted in older policy language. The acute-suicidal-ideation indication is different: for that use, the FDA still requires Spravato be paired with an oral antidepressant.²

If Your Request Is Denied

A provider can appeal a Medi-Cal Rx denial within 180 days of the initial decision. The submission must explicitly use the word “appeal” whether it goes through the Medi-Cal Rx Provider Portal, by fax, or by mail. Without that label, the request will be treated as a brand-new initial review, restarting the clock. Medi-Cal Rx acknowledges the appeal within one calendar day of receipt.¹⁰

Patients enrolled in a Medi-Cal managed care plan can also request an Independent Medical Review through the California Department of Managed Health Care. The IMR is an external review by independent physicians who were not involved in the original decision. Data from the DMHC shows that roughly 61% of health plan decisions reviewed through the IMR process are reversed or overturned.¹¹ Beneficiaries can additionally request a Fair Hearing through the California Department of Social Services without first exhausting internal DHCS processes.⁷

What Coverage Doesn’t Change

Spravato can only be administered under a Risk Evaluation and Mitigation Strategy program. Every dose is self-administered under a provider’s direct observation at a REMS-certified clinic, and each session includes a mandatory two-hour monitoring period tracking blood pressure, sedation, and dissociative symptoms.¹² Patients cannot drive themselves home afterward and are told not to drive or operate heavy machinery until the following day.¹³

The dosing schedule compounds the logistics: twice-weekly visits for the first four weeks, then weekly, then biweekly maintenance. Most major California cities reportedly have at least one REMS-certified clinic accepting Medi-Cal, but provider density is uneven across the state.¹⁴

One boundary worth naming: off-label intravenous or intramuscular ketamine offered at some private clinics is not covered by any California Medi-Cal plan. Only FDA-approved Spravato administered through the REMS program is eligible.

Cost Without Coverage and Manufacturer Help

Without insurance, Spravato’s retail cost runs roughly $1,059 per 56 mg dose and $1,663 per 84 mg dose, before facility and observation fees that can add several hundred dollars per session. A first month of twice-weekly treatment at the lower dose can exceed $5,000 out of pocket.¹⁵ With Medi-Cal coverage in place, patients typically pay little to nothing for the medication itself.

If coverage falls through, the Johnson and Johnson Patient Assistance Program may provide Spravato at no cost for up to one year. Patients with government insurance, including Medi-Cal, can apply if they meet income limits, which cap at $45,180 annually for a single-person household. Applications require a signed enrollment form from the doctor and can be submitted by fax.¹⁶ The Spravato withMe program and independent foundations such as the Patient Advocate Foundation offer additional support.¹⁷

1
CenCal Health. Spravato
2
FDA. Spravato Prescribing Information
3
Blue Shield of California. Esketamine Spravato MCAL UMRx Provider Policy
4
Molina Healthcare. Spravato Esketamine Coverage Policy
5
Centene. Esketamine Spravato Clinical Policy
6
DHCS. Medi-Cal Rx PA Request Form
7
DHCS. Medi-Cal Rx Prior Authorization
8
AJMC. When the Label Changes Do Coverage Policies Follow
9
NPR. FDA Allows Standalone Use of Nasal Spray Antidepressant Spravato Esketamine
10
DHCS. PA Claim Appeals Reminder
11
California Chronic Care. California Independent Medical Review Results
12
FDA. Spravato REMS Program
13
Janssen. Spravato REMS for Healthcare Professionals
14
Healing Maps. Does California’s Medi-Cal Insurance Cover Ketamine
15
SingleCare. Spravato Without Insurance
16
Janssen. Johnson and Johnson Patient Assistance Program Quick Reference Guide
17
Janssen CarePath. State Sponsored and Assistance Foundations